Gsk Plc · LSE:GSK
Gsk — Merger or Acquisition (January 2026)
10 slides from Gsk's merger presentation, Jan 20, 2026
Slide 1: Agreement to acquire RAPT Therapeutics
20 January 2026 Agreement to acquire RAPT Therapeutics Lead asset: ozureprubart, a potential best-in-class, long-acting anti-IgE monoclonal antibody for food allergy gsk.com
Slide 2: Speakers
Speakers Luke Miels Nina Mojas Tony Wood Chief Executive Officer President, Global Product Chief Scientific Officer Strategy
Slide 3: Disclosure statement
Disclosure statement This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer or a recommendation to sell securities, nor is it a substitute for the tender offer materials that Redrose Acquisition Co., GlaxoSmithKline LLC and GSK plc wi
Slide 4: Cautionary statement regarding forward-looking statements
Cautionary statement regarding forward-looking statements GSK plc cautions investors that any forward-looking statements or projections made by GSK plc, including those made in this communication, are subject to risks and uncertainties that may cause actual results to differ materially from those pr
Slide 5: Agreement to acquire RAPT Therapeutics
Agreement to acquire RAPT Therapeutics Ozureprubart: potentially best-in-class, long-acting anti-IgE in phase IIb for food allergy (FA) Strategic rationale Financial considerations • Significant unmet need with >1.3m people • Deal consideration $2.2bn impacted by severe FA in the US1 • GSK acquires
Slide 6: Food allergy has high unmet need with limited treatment options
Food allergy has high unmet need with limited treatment options Rapid uptake of approved anti-IgE antibody in food allergy demonstrates unmet need Food allergy US uptake of anti-IgE Ab therapy3 • >3m US patient visits each year to hospital/emergency care due to severe food allergies1 • ~$33bn cost t
Slide 7: Anti-IgE use in proactive management requires a complex dosing schedule
Anti-IgE use in proactive management requires a complex dosing schedule Proactive management is required for high-risk patients, or where standard management1 is insufficient Proactive management2,3 Approved anti-IgE dosing schedule4 Ozureprubart has potential to achieve: Single allergy (peanut) All
Slide 8: Anti-IgE: Clinically validated in allergic diseases
Anti-IgE: Clinically validated in allergic diseases Omalizumab approved in allergic asthma, CRSwNP, CSU and food allergy (US only) Anti-IgE MOA in food allergy • Binds & sequesters circulating IgE Anti-IgE mAb • Blocks FcεRI cross-linking on mast cells • Reduces CD23-mediated inflammation amplificat
Slide 9: Ozureprubart has a longer half-life, deeper and sustained pharmacodynamics with comparable efficacy
Ozureprubart has a longer half-life, deeper and sustained pharmacodynamics with comparable efficacy vs approved anti-IgE, and less frequent dosing Phase I Half-life 60 days vs omalizumab 26 days Phase II in chronic spontaneous urticaria3 Pharmacodynamics (free IgE) deeper and more sustained reductio
Slide 10: 10
10